Intended pharmacotherapeutical approaches of Alzheimer's disease therapy;Zvažované farmakoterapeutické přístupy léčby Alzheimerovy choroby

Ceska a Slovenska Farmacie

Volumn 61, Issue 1-2, 2012, Pages 4-10

  Korábečný, Jan ^a,b   Hrubá, Eva ^a   Soukup, Ondřej ^b   Zemek, Filip ^b   Musílek, Kamil ^c   Nepovímová, Eugenie ^a   Špilovská, Katarína ^b   Opletalová, Veronika ^a   Kuča, Kamil ^d  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

^c UNIVERSITY OF HRADEC KRALOVE   (Czech Republic)

^d Univerzita Obrany   (Czech Republic)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Beta amyloid; Tau protein; Therapeutic approaches

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMANTINE; N METHYLASPARTIC ACID;

ALZHEIMER DISEASE; CHEMICAL STRUCTURE; DRUG MECHANISM; HUMAN; MEDICAL RESEARCH; REVIEW; DRUG ANTAGONISM;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; HUMANS; MEMANTINE; N-METHYLASPARTATE;

EID: 84861945987     PISSN: 12107816     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Alzheimer's Association. 2011 Alzheimer's disease facts and figures. Alzheimers Dement 2011; 7, 208-244.
2. Herrup K. Re imaginizing Alzheimer' disease - an age-based hypothesis. J Neurosci 2010; 30, 16755-16762
3. Drtinova L., Pohanka M. Alzheimerova demence: aspekty současné farmakologické léčby. Čes slov Farm 2011; 60, 219-228.
4. Craig D., Mirakhur A., Hart D. J., McIlroy S. P., Passmore A. P. A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease. Am J Geriat Psychiat 2005; 13, 460-468.
5. Ballard C, Gauthier S., Corbett A., Brayne C., Aarsland D., Jones E. Alzheimer's disease. Lancet 2011; 377, 1019-1031.
6. Brodaty H., Breteler M. M., Dekosky S. T., Dorenlot P., Fratiglioni L., Hock C., Kenigsberg P. A., Scheltens P., De Strooper B. The world of dementia beyond 2020. J Am Geriatr Soc 2011; 59, 923-927.
7. Souder E., Beck C. Overview of Alzheimer's disease. Nurs Clin N Am 2004; 39, 545-559. (Pubitemid 39149810)
8. Kim K. Y., Wood B. E., Wilson M. I. Risk factors for Alzheimer's disease: An overview for clinical practitioners. Consult Pharm 2005; 20, 224-230. (Pubitemid 40387685)
9. Bateman R. J., Aisen P. S., De Strooper B., Fox N. C, Lemere C. A., Ringman J. M., Salloway S., Sperling R. A., Windisch M., Xiong C. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 2011; 3, 1-13.
10. Giacobini E. Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease? CNS Drugs 2001; 15, 85-91. (Pubitemid 32195104)
11. Giacobini E., Mori F., Lai C. C. The effect of cholinesterase inhibitors on the secretion of APPS from rat brain cortex. Ann NY Acad Sci. 1996; 777, 393-398. (Pubitemid 26149220)
12. Knapp M. J., Knopman D. S., Solomon P. R., Pendlebury W. W., Davis C. S., Gracon S. I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271, 985-991. (Pubitemid 24099918)
13. Dejmek L. 7-Meota. Drug Future 1990; 15, 126-129. (Pubitemid 20161917)
14. Korabecny J., Musilek K., Holas O., Binder J., Zemek F., Marek J., Pohanka M., Opletalova V., Dohnal V., Kuca K. Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinestrase inhibitors in Alzhemeir disease. Bioorg Med Chem Lett 2010; 20, 6093-6095.
15. Korabecny J., Holas O., Musilek K., Pohanka M., Opletalova V., Dohnal V., Kuca K. Synthesis and in vitro evaluation of new tacrine derivatives-bis- alkylene linked 7-MEOTA. Lett Org Chem 2010; 7, 327-331.
16. Korabecny J., Musilek K, Holas O., Nepovimova E., Jun D., Zemek F., Opletalova V., Patocka J., Dohnal V., Nachon F., Hroudova J., Fisar Z., Kuca K. Synthesis and in vitro evaluation of N-(bromobut-3-en-2-yl)-7-methoxy-1,2,3,4- tetrahydroacridin-9-amine as a cholinesterase inhibitor with regard to Alzheimer's disease treatment. Molecules 2010; 15, 8804-8812.
17. Korabecny J., Musilek K., Zemek F., Horova A., Holas O., Nepovimova E., Opletalova V., Hroudova J., Fisar Z., Jung Y.-S., Kuca K. Synthesis and in vitro evaluation of 7-methoxy-N-(pent-4-enyl)-1,2,3,4-tetrahydroacridin-9-amine - new tacrine derivative with cholinergic properties. Bioorg Med Chem Lett 2011; 21, 6563-6556.
18. Fang L, Appenroth D., Decker M., Kiehntopf M., Lupp A., Peng S., Fleck C, Zhang Y., Lehman J. NO-donating tacrine hybrid compounds improve scopolamine-induced cognition impairment and show less hepatotoxicity. J Med Chem 2008; 51, 7666-7669.
19. Trinh, N. H., Hoblyn, J., Mohanty, S., Yaffe, K. Efficacy of cholinesterases inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003; 289, 210-216. (Pubitemid 36068709)
20. Kamal, M. A., Klein, P., Yu, Q. S., Tweedie, D., Li, Y., Holloway, H. W., Tweedie, D., Greig, N. H. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. J Alzheimers Dis 2006; 10, 43-51. (Pubitemid 44401365)
21. Li F., Tsien J. Z. Memory and the NMDA receptors. New Engl J Med 2009; 361, 302-303.
22. Harkany T., Abraham I., Timmerman W., Laskay G., Toth B., Safari M., Konya C, Sebens J. B., Korf J., Nyakas C, Zarandi M., Soos K., Penke B., Luiten P. G. Beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci 2000; 12, 2735-2745.
23. Amadoro G., Ciotti M. T., Costanzi M., Cestari V., Calissano P., Canu N. NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. P Natl Acad Sci USA 2006; 103, 2892-2897.
24. Sonkusare S. K., Kaul C. L., Ramarao P. Dementia of Alzheimer's disease and other neurodegenerative disorders-memantine, a new hope. Pharmacol Res 2005; 51, 1-17. (Pubitemid 39425068)
25. Tariot P. N., Farlow M. R., Grossberg G. T., Graham S. M., McDonald S., Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291, 317-324. (Pubitemid 38101604)
26. Wenk G. L., Baker L. M., Stoehr J. D., Hauss-Wegrzyniak B., Danysz W. Neuroprotection by novel antagonists at the NMDA receptor channel and glycineB sites. Eur J Pharmacol. 1998; 347, 183-187. (Pubitemid 28234454)
27. Schenk D., Barbour R., Dunn W., Gordon G, Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G, Vasquez N., Vandevert C, Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-diseaselike pathology in the PDAPP mouse. Nature 1999; 400, 173-177. (Pubitemid 29327547)
28. Lavie V., Becker M., Cohen-Kupiec R., Yacoby I., Koppel R., Wedenig M., Hutter-Paier B., Solomon B. EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials. J Mol Neurosci 2004; 24, 105-113. (Pubitemid 41359175)
29. Orgogozo J. M., Gilman S., Dartigues J. F., Laurent B., Puel M., Kirby L. C, Jouanny P., Dubois B., Eisner L., Flitman S., Michel B. F., Boada M., Frank A., Hock C. Subacute meningoencephalitis in a subset of patients with AD after A beta 42 immunization. Neurology 2003; 61, 46-54. (Pubitemid 36818745)
30. Hock C, Konietzko U., Streffer J. R., Tracy J., Signorell A., Müller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Wollmer M. A., Umbricht D., de Quervain D. J., Hofmann M., Maddalena A., Papassotiropoulos A., Nitsch R. M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38, 547-554. (Pubitemid 36645030)
31. Fox N. C, Black R. S., Gilman S., Rossor M. N., Griffith S. G., Jenkins L., Koller M. Effects of A beta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005; 64, 1563-1572. (Pubitemid 40617692)
32. Dodel R. C, Du Y., Depboylu C, Hampel H., Frölich L., Haag A., Hemmeter U., Paulsen S., Teipel S. J., Brettschneider S., Spottke A., Nölker C, Möller H. J., Wei X., Farlow M., Sommer N., Oertel W. H. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosur Ps 2004; 75, 1472-1474. (Pubitemid 39279821)
33. Asai M., Hattori C, Iwata N., Saido T. C, Sasagawa N., Szabó B., Hashimoto Y., Maruyama K, Tanuma S., Kiso Y., Ishiura S. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem 2006; 96, 533-540.
34. Wong P. BACE. Alzheimers Dement 2005; 1, S3.
35. Citron M. Beta-secretase inhibition for the treatment of Alzheimer's disease-promise and challenge. Trends Pharmacol Sci 2004; 25, 92-97. (Pubitemid 38183395)
36. Mancini F., de Simone A., Andrisano V. Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors. Anal Bioanal Chem 2011; 400, 1979-1996.
37. Lanz T. A., Himes C. S., Pallante G., Adams L., Yamazaki S., Amore B., Merchant K. M. The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L- alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plazma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther 2003; 305, 864-871. (Pubitemid 36617962)
38. El Mouedden M., Vandermeeren M., Meert T., Mercken M. Reduction of A beta levels in the Sprague Dawley rat after oral administrativ of the functional gamma-secretase inhibitor, DAPT: a novel non-transgenic model for A beta production inhibitors. Curr Pharm Design 2006; 12, 671-676.
39. May P. C, Yang Z., Li W., Hyslop P. A., Siemers E., Boggs L. N. Multi-compartmental pharmacodynamic assessment of the functional gamma-secretase inhibitor LY450139 dihydrate in PDAPP transgenic mice and non-transgenic mice. Neurobiol Aging 2004; 25, S65.
40. Barten D. M., Guss V. L., Cosa J. A., Loo A., Hansel S. B., Zheng M., Munoz B., Srinivasan K., Wang B., Robertson B. J., Polson C. T., Wang J., Roberts S. B., Hendrick J. P., Anderson J. J., Loy J. K., Denton R., Verdoorn T. A., Smith D. W., Felsenstein K. M. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J Pharmacol Exp Ther 2005; 312, 635-643. (Pubitemid 40189561)
41. Imbimbo B. P. Alzheimer's disease: gamma secretase inhibitors. Drug Discov Today: Therapeutic Strategies 2008; 5, 169-175.
42. Weggen S., Eriksen J. L., Sagi S. A., Pietrzik C. U., Golde T. E., Koo E. H. A beta 42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem 2003; 278, 30748-30754. (Pubitemid 36994581)
43. Becker R. E., Greig N. H. Why so few drugs for Alzheimer's disease? Are methods failing drugs? Curr Alzheimer Res 2010; 7, 642-651.
44. Mintzer J. E., Wilcock G. K., Black S. E., Zavitz K. H, Hendrix S. B. MPC-7869, a selective Abeta42-lowering agent, delays time to clinically significant psychiatric adverse events in Alzheimer's disease: analysis from a 12-month phase 2 trial. Presented as a poster exhibit at the 10th International Conference on Alzheimer's Disease and Related Disorders; 2006 Jul 15-20; Madrid, Spain.
45. Aisen P. S., Gauthier S., Vellas B., Briand R., Saumier D., Laurin J., Garceau D. Alzhemed: A potential treatment for Alzheimer's disease. Curr Alzheimer Res 2007; 4, 473-478. (Pubitemid 47416642)
46. Bilikiewicz A., Gaus W. Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease. J Alzheimer Dis 2004; 6, 17-26. (Pubitemid 38418554)
47. Leszek J., Inglot A. D., Janusz M., Byczkiewicz F., Kiejna A., Georgiades J., Lisowski J. Colostrinin proline-rich polypeptide complex from ovine colostrum - a long-term study of its efficacy in Alzheimer's disease. Med Sci Monitor 2002; 8, PI93-PI96. (Pubitemid 35257340)
48. Townsend M., Cleary J. P., Mehta T., Hofmeister J., Lesne S., O'Hare E., Walsh D. M., Selkoe D. J. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol 2006; 60, 668-676. (Pubitemid 46048484)
49. Fassbender K., Simons M., Bergmann C, Stroick M., Lutjohann D., Keller P., Runz H., Kuhl S., Bertsch T., von Bergmann K., Hennerici M., Beyreuther K., Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides A beta 42 and A beta 40 in vitro and in vivo. P Natl Acad Sci USA 2001; 98, 5856-5861. (Pubitemid 32435732)
50. Wolozin B., Kellman W., Ruosseau P., Celesia G. G., Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57, 1439-1443.
51. Li G., Higdon R., Kukull W. A., Peskind E., Moore K. V., Tsuang D., van Belle G., McCormick W., Bowen J. D., Teri L., Schellenberg G. D., Larson E. B. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004; 63, 1624-1628. (Pubitemid 39507579)
52. Jick H., Zornberg G. L., Jick S. S., Seshadri S., Drachman D. A. Statins and the risk of dementia. Lancet 2000; 356, 1627-1631.
53. Rockwood K., Kirkland S., Hogan D. B., MacKnight C, Merry H, Verreault R., Wolfson C, McDowell I. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002; 59, 223-227. (Pubitemid 34240938)
54. McGuiness B., O'Hare J., Craig D., Bullock R., Malouf R., Passmore P. Statins for the treatment of dementia (Review). Cochrane Database Syst Rev 2010; 4.
55. Yaffe K., Barrett-Connor E., Lin F., Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002; 59, 378-384. (Pubitemid 34208144)
56. Rea T. D., Breitner J. C, Psaty B. M., Fitzpatrick A. L., Lopez O. L., Newman A. B., Hazzard W. R., Zandi P. P., Burke G. L., Lyketsos C. G., Bernick C, Kuller L. H. Statin use and the risk of incident dementia: the cardiovascular health study. Arch Neurol 2005; 62, 1047-1051. (Pubitemid 41043724)
57. Shepherd J., Blauw G. J., Murphy M. B., Bollen E. L., Buckley B. M., Cobbe S. M., Ford I., Gaw A., Hyland M., Jukema J. W., Kamper A. M., Macfarlane P. W., Meinders A. E., Norrie J., Packard C. J., Perry I. J., Stott D. J., Sweeney B. J., Twomey C., Westendorp R. G.; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360, 1623-1630. (Pubitemid 35379733)
58. Zandi P. P., Sparks D. L., Khachaturian A. S., Tschanz J., Norton M., Steinberg M., Welsh-Bohmer K. A., Breitner J. C.; Cache County Study investigators. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005; 62, 217-224. (Pubitemid 40189139)
59. Wang Q., Yan J., Chen X., Li J., Yang Y., Weng J., Deng C, Yenari M. A. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol 2011; 230, 27-34.
60. Craft S. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging 2005; 26, S65-S69. (Pubitemid 41739429)
61. Pedersen W. A., McMillan P. J., Kulstad J. J., Leverenz J. B., Craft S., Haynatzki G. R. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 2006; 199, 265-273. (Pubitemid 43928978)
62. Watson G. S., Cholerton B. A., Reger M. A., Baker L. D., Plymate S. R., Asthana S., Fishel M. A., Kulstad J. J., Green P. S., Cook D. G., Kahn S. E., Keeling M. L., Craft S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriat Psychiat 2005; 13, 950-958. (Pubitemid 46638661)
63. Geldmacher D. S., Frolich L., Doody R. S., Erkinjuntti T., Vellas B., Jones R. W., Banerjee S., Lin P., Sano M. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging 2006; 10, 417-429. (Pubitemid 44845354)
64. Craft S. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alz Dis Assoc Dis 2006; 20, 298-301. (Pubitemid 44900946)
65. Gupta A., Bisht B., Dey C. S. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 2011; 60, 910-920.
66. Cuajungco M. P., Frederickson C. J., Bush A. I. Amyloid-beta metal interaction and metal chelation. Sub-Cell Biochem 2005; 38, 235-254.
67. Cherny R. A., Atwood C. S., Xilinas M. E., Gray D. N., Jones W. D., McLean C. A., Barnham K. J., Volitakis I., Fraser F. W., Kim Y., Huang X., Goldstein L. E., Moir R. D., Lim J. T., Beyreuther K., Zheng H., Tanzi R. E., Masters C. L., Bush A. I. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001; 30, 665-676. (Pubitemid 32607332)
68. Ritchie C. W., Bush A. I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., Kiers L., Cherny R., Li Q. X., Tammer A., Carrington D., Mavros C, Volitakis I., Xilinas M., Ames D., Davis S., Beyreuther K., Tanzi R. E., Masters C. L. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003; 60, 1685-1691. (Pubitemid 37521621)
69. Dedeoglu A., Cormier K., Payton S., Tseitlin K. A., Kremsky J. N., Lai L., Li X., Moir R. D., Tanzi R. E., Bush A. I., Kowall N. W., Rogers J. T., Huang X. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. Exp Gerontol 2004; 39, 1641-1649. (Pubitemid 39585199)
70. Lee J. Y., Friedman J. E., Angel I., Kozak A., Koh J. Y. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol Aging 2004; 25, 1315-1321. (Pubitemid 39299169)
71. Reznichenko L., Amit T., Zheng H., Avramovich-Tirosh Y., Youdim M. B., Weinreb O., Mandel, S. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J Neurochem 2006; 97, 527-536.
72. Fisher A., Pittel Z., Haring R., Bar-Ner N., Kliger-Spatz M., Natan N., Egozi I., Sonego H., Marcovitch I., Brandeis R. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy. J Mol Neurosci 2003; 20, 349-356. (Pubitemid 38146993)
73. Fisher A., Brandeis R., Bar-Ner R. H., Kliger-Spatz M., Natan N., Sonego H, Marcovitch I., Pittel Z. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. J Mol Neurosci 2002; 19, 145-153. (Pubitemid 35013348)
74. Caccamo A., Fisher A., Laferla F. M. M1 Agonists as a potential disease-modifying therapy for Alzheimer's disease. Curr Alzheimer Res 2009; 6, 112-117.
75. Caccamo A., Oddo S., Billings L. M., Green K. N., Martinez-Coria H., Fisher A., LaFerla F. M. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 2006; 49, 671-682. (Pubitemid 43290127)
76. Hock C, Maddalena A., Raschig A., Müller-Spahn F., Eschweiler G., Hager K., Heuser I., Hampel H., Müller-Thomsen T., Oertel W., Wienrich M., Signorell A., Gonzalez-Agosti C, Nitsch R. M. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta (42) in patients with Alzheimer's disease. Amyloid 2003; 10, 1-6. (Pubitemid 36520922)
77. Bodick N. C, Offen W. W., Levey A. I., Cutler N. R., Gauthier S. G., Satlin A., Shannon H. E., Tollefson G. D., Rasmussen K., Bymaster F. P., Hurley D. J., Potter W. Z., Paul S. M. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997; 54, 465-473. (Pubitemid 27172867)
78. Fang L., Jumpertz S., Zhang Y., Appenroth D., Fleck C, Mohr K., Tränkle C, Decker M. Hybrid molecules from xanomeline and tacrine: enhanced tacrine actions on cholinesterases and muscarinic M1 receptors. J Med Chem 2010; 53, 2094-2103.
79. Mulugeta E., Karlsson E., Islam A., Kalaria R., Mangat H., Winblad B., Adem A. Loss of muscarinic M4 receptors in hippocampus of Alzheimer patients. Brain Res 2003; 960, 259-262. (Pubitemid 36044584)
80. Heinrich JN, Butera JA, Carrick T, Kramer A, Kowal D, Lock T, Marquis KL, Pausch MH, Popiolek M, Sun SC, Tseng E, Uveges AJ, Mayer SC. Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol 2009; 605, 53-56.
81. Neeper M., Schmidt A. M., Brett J., Yan S. D., Wang F., Pan Y. C, Elliston K., Stern D., Shaw A. Cloning and expression of a cell-surface receptor for advanced glycosylation end-products of proteins. J Biol Chem 1992; 267, 14998-15004.
82. Mackic J. B., Stins M., McComb J. G., Calero M., Ghiso J., Kim K. S., Yan S. D., Stern D., Schmidt A. M., Frangione B., Zlokovic B. V. Human blood-brain barrier receptors for Alzheimer's amyloid-h 1-40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J Clin Invest 1998; 102, 734-743. (Pubitemid 28399606)
83. Deane R., Du Yan S., Submamaryan R. K., LaRue B., Jovanovic S., Hogg E., Welch D., Manness L., Lin C, Yu J., Zhu H., Ghiso J., Frangione B., Stern A., Schmidt A. M., Armstrong D. L., Arnold B., Liliensiek B., Nawroth P., Hofman F., Kindy M., Stern D., Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003; 9, 907-913. (Pubitemid 36889934)
84. Matsuoka Y., Saito M., LaFrancois J., Saito M., Gaynor K., Olm V., Wang L., Casey E., Lu Y., Shiratori C, Lemere C, Duff K. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to betaamyloid. J Neurosci 2003; 23, 29-33. (Pubitemid 36050401)
85. Bachmeier C, Beaulieu-Abdelahad D., Mullan M., Paris D. Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier. Eur J Pharmacol 2011; 659, 124-129.